# SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

> **NCT02036645** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 77 (actual)

## Conditions studied

- Mild-Moderate Alzheimer's Disease
- Healthy Elderly

## Interventions

- **BIOLOGICAL:** MEDI1814 for IV injection
- **BIOLOGICAL:** MEDI1814 for Subcutaneous Injection
- **BIOLOGICAL:** IV Placebo
- **BIOLOGICAL:** Placebo for Subcutaneous Injection

## Key facts

- **NCT ID:** NCT02036645
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-04
- **Primary completion:** 2016-09-15
- **Final completion:** 2016-09-15
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036645, "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02036645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*